The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

Myriad Genetics, Inc. MYGN recently launched a new educational website, Know More Sooner, which provides comprehensive ...

Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and ...

Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...

Larry Robbins is an American hedge fund manager, philanthropist, and the founder, CEO, and portfolio manager of Glenview Capital, […] Myriad Genetics launches an online prenatal genetic testing ...

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer prognostic ...

SAN FRANCISCO — At the JP Morgan Healthcare Conference here on Wednesday, Myriad Genetics CEO Paul Diaz provided preliminary Q4 and full-year 2024 financial results, as well as full-year 2025 guidance ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...